Cooper Companies Reports $77.9M Net Loss in Q2 Due to $271.6M Litigation Charge
COO is trading near its 52-week low of $58.89 (14% above the low) on elevated volume (3.6× avg).
Summary
Cooper Companies reported a Q2 2026 net loss of $77.9 million, resulting in diluted EPS of ($0.40), despite revenue growing 7.9% to $1.08 billion. This net loss is primarily attributed to a $271.6 million litigation accrual within its CooperSurgical segment, as detailed in the recently filed 10-Q. While earlier reports focused on adjusted earnings beats, this headline highlights the GAAP loss. The substantial litigation charge significantly impacted the company's profitability, turning what would otherwise be a revenue growth story into a net loss for the quarter.
At the time of this announcement, COO was trading at $66.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $58.89 to $89.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.